Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
29
06
2021
accepted:
01
10
2021
revised:
22
09
2021
pubmed:
8
12
2021
medline:
4
5
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
People with severe mental illness (SMI; including schizophrenia/psychosis, bipolar disorder (BD), major depressive disorder (MDD)) experience large disparities in physical health. Emerging evidence suggests this group experiences higher risks of infection and death from COVID-19, although the full extent of these disparities are not yet established. We investigated COVID-19 related infection, hospitalisation and mortality among people with SMI in the UK Biobank (UKB) cohort study. Overall, 447,296 participants from UKB (schizophrenia/psychosis = 1925, BD = 1483 and MDD = 41,448, non-SMI = 402,440) were linked with healthcare and death records. Multivariable logistic regression analysis was used to examine differences in COVID-19 outcomes by diagnosis, controlling for sociodemographic factors and comorbidities. In unadjusted analyses, higher odds of COVID-19 mortality were seen among people with schizophrenia/psychosis (odds ratio [OR] 4.84, 95% confidence interval [CI] 3.00-7.34), BD (OR 3.76, 95% CI 2.00-6.35), and MDD (OR 1.99, 95% CI 1.69-2.33) compared to people with no SMI. Higher odds of infection and hospitalisation were also seen across all SMI groups, particularly among people with schizophrenia/psychosis (OR 1.61, 95% CI 1.32-1.96; OR 3.47, 95% CI 2.47-4.72) and BD (OR 1.48, 95% CI 1.16-1.85; OR 3.31, 95% CI 2.22-4.73). In fully adjusted models, mortality and hospitalisation odds remained significantly higher among all SMI groups, though infection odds remained significantly higher only for MDD. People with schizophrenia/psychosis, BD and MDD have higher risks of COVID-19 infection, hospitalisation and mortality. Only a proportion of these disparities were accounted for by pre-existing demographic characteristics or comorbidities. Vaccination and preventive measures should be prioritised in these particularly vulnerable groups.
Identifiants
pubmed: 34873324
doi: 10.1038/s41380-021-01344-2
pii: 10.1038/s41380-021-01344-2
pmc: PMC9054655
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248-1255Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T021780/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR301206
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br. J. Psychiatry. 2011;6:441–2.
doi: 10.1192/bjp.bp.111.092718
Maj M. Physical health care in persons with severe mental illness: a public health and ethical priority. World Psychiatry. 2009;8:1–2.
doi: 10.1002/j.2051-5545.2009.tb00196.x
Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.
doi: 10.1016/S2215-0366(19)30132-4
Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–80.
doi: 10.1002/wps.20420
Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166–74.
doi: 10.1002/wps.20309
Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–47.
doi: 10.1002/wps.20252
Swaraj S, Wang M, Chung D, Curtis J, Firth J, Ramanuj PP, et al. Meta-analysis of natural, unnatural and cause-specific mortality rates following discharge from in-patient psychiatric facilities. Acta Psychiatr Scand. 2019;140:244–64.
doi: 10.1111/acps.13073
Campos LN, Guimarães MDC, Carmo RA, Melo APS, De Oliveira HN, Elkington K, et al. HIV, syphilis, and hepatitis B and C prevalence among patients with mental illness: a review of the literature. 2008; 24:s607–20.
Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3:40–8.
doi: 10.1016/S2215-0366(15)00357-0
Fekadu A, Medhin G, Kebede D, Alem A, Cleare AJ, Prince M, et al. Excess mortality in severe mental illness: 10-Year population-based cohort study rural Ethiopia. Br J Psychiatry. 2015;206:289–96.
doi: 10.1192/bjp.bp.114.149112
Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015;37:199–222.
doi: 10.1016/j.genhosppsych.2015.03.004
Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31–7.
doi: 10.2105/AJPH.91.1.31
Bauer-Staeb C, Jörgensen L, Lewis G, Dalman C, Osborn DPJ, Hayes JF. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017;4:685–93.
doi: 10.1016/S2215-0366(17)30253-5
Sara G, Chen W, Large M, Ramanuj P, Curtis J, McMillan F, et al. Potentially preventable hospitalisations for physical health conditions in community mental health service users: a population-wide linkage study. Epidemiol Psychiatr Sci. 2021;30:e22.
doi: 10.1017/S204579602100007X
Wang Q, Xu R, Volkow ND. Increased risk of COVID‐19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20:124–30.
doi: 10.1002/wps.20806
Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;S2215-0366:00232–7.
Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 Countries. JAMA Psychiatry. 2021. https://doi.org/10.1001/jamapsychiatry.2021.2274 .
Toubasi AA, AbuAnzeh RB, Tawileh HBA, Aldebei RH, Alryalat SAS. A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res. 2021;299:113856.
doi: 10.1016/j.psychres.2021.113856
The Lancet Psychiatry. A matter of priority: COVID-19 vaccination and mental health. Lancet Psychiatry. 2021;7:551.
doi: 10.1016/S2215-0366(21)00209-1
De Hert M, Mazereel V, Detraux J, Van Assche K. Prioritizing COVID‐19 vaccination for people with severe mental illness. World Psychiatry. 2021;20:54–5.
doi: 10.1002/wps.20826
Maripuu M, Bendix M, Öhlund L, Widerström M, Werneke U. Death associated with coronavirus (COVID-19) infection in individuals with severe mental disorders in Sweden during the early months of the outbreak—an exploratory cross-sectional analysis of a population-based register study. Front Psychiatry. 2021;11:609579.
doi: 10.3389/fpsyt.2020.609579
Jeon H-L, Kwon JS, Park S-H, Shin J-Y. Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study. Br J Psychiatry. 2021;218:344–51.
doi: 10.1192/bjp.2020.251
Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. Am Med Assoc. 2021;78:380–6.
Batty GD, Altschul D, Batty D. Pre-pandemic mental and physical health as predictors of COVID-19 vaccine hesitancy: evidence from a UK-wide cohort study. medRxiv. 2021;04.27.21256185.
Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank Community Cohort. J Gerontol - Ser A Biol Sci Med Sci. 2020;75:2224–30.
doi: 10.1093/gerona/glaa183
van der Meer D, Pinzón-Espinosa J, Lin BD, Tijdink JK, Vinkers CH, Guloksuz S, et al. Associations between psychiatric disorders, COVID-19 testing probability and COVID-19 testing results: findings from a population-based study. BJPsych Open. 2020;6:e87.
doi: 10.1192/bjo.2020.75
Yang H, Chen W, Hu Y, Chen Y, Zeng Y, Sun Y, et al. Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank cohort analysis. Lancet Heal Longev. 2020;1:e69–79.
doi: 10.1016/S2666-7568(20)30013-1
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
doi: 10.1371/journal.pmed.1001779
Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.
doi: 10.1136/bmj.m3731
Li L, Li F, Fortunati F, Krystal JH. Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) Infection. JAMA Netw Open. American Medical Association; 2020;3:e2023282–82.
Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, et al. COVID-19 Prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study. Schizophr Bull. 2021;47:1211–7.
doi: 10.1093/schbul/sbab012
Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun. 2020;88:44–9.
doi: 10.1016/j.bbi.2020.05.074
Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021;397:1711–24.
doi: 10.1016/S0140-6736(21)00634-6
Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9:233.
doi: 10.1038/s41398-019-0570-y
Thwaites RS, Uruchurtu ASS, Siggins MK, Liew F, Russell CD, Moore SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6:9873.
doi: 10.1126/sciimmunol.abg9873
Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186:1026–34.
doi: 10.1093/aje/kwx246
Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11:1–12.
doi: 10.1038/s41467-020-19478-2
Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J. et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PLoS ONE. 2012; https://doi.org/10.1371/journal.pone.0031660 .
doi: 10.1371/journal.pone.0031660
pubmed: 22457710
pmcid: 3310436
Govind R, Fonseca de Freitas D, Pritchard M, Hayes RD, MacCabe JH. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psychiatry. 2020;219:368–74.
doi: 10.1192/bjp.2020.151
Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020;61:411–27.
doi: 10.1016/j.psym.2020.05.006